[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 835875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan  Anderman J.D.", "title": "VP, Head of Legal & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.43, "open": 1.6, "dayLow": 1.52, "dayHigh": 2.68, "regularMarketPreviousClose": 1.43, "regularMarketOpen": 1.6, "regularMarketDayLow": 1.52, "regularMarketDayHigh": 2.68, "beta": 0.746, "forwardPE": -4.876386, "volume": 24155169, "regularMarketVolume": 24155169, "averageVolume": 479904, "averageVolume10days": 365870, "averageDailyVolume10Day": 365870, "bid": 1.84, "ask": 1.89, "bidSize": 100, "askSize": 100, "marketCap": 255915520, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 2.68, "priceToSalesTrailing12Months": 301.0771, "fiftyDayAverage": 1.5752, "twoHundredDayAverage": 1.47104, "currency": "USD", "enterpriseValue": 127390856, "floatShares": 88570277, "sharesOutstanding": 137588992, "sharesShort": 2102394, "sharesShortPriorMonth": 1225366, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.0153, "heldPercentInsiders": 0.12550001, "heldPercentInstitutions": 0.6916, "shortRatio": 4.14, "shortPercentOfFloat": 0.0216, "impliedSharesOutstanding": 137588992, "bookValue": 1.006, "priceToBook": 1.8489065, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -47757000, "trailingEps": -0.35, "forwardEps": -0.51, "enterpriseToRevenue": 149.872, "enterpriseToEbitda": -2.323, "52WeekChange": -0.19209039, "SandP52WeekChange": 0.23806548, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CMPX", "underlyingSymbol": "CMPX", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "firstTradeDateEpochUtc": 1617629400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2da7fead-7fe9-351a-a396-4dd759234d3a", "messageBoardId": "finmb_266166780", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.86, "targetHighPrice": 32.0, "targetLowPrice": 4.0, "targetMeanPrice": 11.0, "targetMedianPrice": 9.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 135402000, "totalCashPerShare": 0.984, "ebitda": -54834000, "totalDebt": 6877000, "quickRatio": 30.544, "currentRatio": 31.838, "totalRevenue": 850000, "debtToEquity": 4.969, "revenuePerShare": 0.006, "returnOnAssets": -0.21712999, "returnOnEquity": -0.32004002, "freeCashflow": -31852500, "operatingCashflow": -48047000, "grossMargins": 1.0, "operatingMargins": -65.22824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-09"}]